• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Theraclion partner UVA wins FDA nod for combined HIFU, immunotherapy breast cancer trial

June 27, 2017 By Fink Densford

Theraclion

Theraclion said yesterday its academic development partner, the University of Virginia, won  an FDA nod to launch a study of the combined use of echotherapy high intensity focused ultrasound and immunotherapy drug pembrolizumab for treating patients with breast cancer.

The study will examine the combined treatment’s effect on fighting breast cancer tumor cells, the French company said. Theraclion is hopeful that HIFU treatment may locally potentiate immune responses induced by the immunotherapy drugs.

“Immunotherapy treatments help the body to fight against cancerous cells. This new treatment method is expected to have fewer side effects than existing cancer treatment alternatives. Nevertheless, large, solid masses are difficult for the immune system to access,” Dr. Patrick Dillon of the University of Virginia said in a prepared statement

“The HIFU treatment could be used to pre-treat a tumor in order to shrink the overall volume and, perhaps more importantly, allow the patient’s own immune system to access and recognize the malignant cells,” UVA breast care program co-director Dr. David Brenin said in prepared remarks.

In the trial, researchers will use Theraclion’s Echopulse HIFU system, which it said is currently being evaluated in a feasibility study in the US for non-invasive treatment of breast fibroadenomas.

“To our knowledge, this will be the first study combining HIFU and immunotherapy drugs in the field of breast cancer. Our system is specifically adapted for this combination treatment, as it is the only robotic system with flexible access to the target. We are eager to see this kind of investigation, as we have always committed to our customers and shareholders that we will leverage our outstanding clinical results in benign tumors into progress treating malignant disease. This is a critical milestone for today’s breast users, gynecologists, oncologists and radiologists, who are excited to explore this new path in the fight against cancer,” Theraclion CEO David Caumartin said in a press release.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Regulatory/Compliance Tagged With: Theraclion

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS